The trial compared Tafa-Len-R-CHOP to R-CHOP alone, the current standard of care, for efficacy and safety.

Adding tafasitamab and lenalidomide to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) may offer a meaningful advance for patients with newly diagnosed high-risk diffuse ...

R-CHOP is a combination of five drugs that work together to target and kill cancer cells. It’s a first-line treatment for aggressive non-Hodgkin’s lymphoma, a group of blood cancers. Most often, ...

Although ibrutinib adds to the cost of treatment, its benefits over the long term justify the cost, investigators found. Adding ibrutinib (Imbruvica) to the R-CHOP regimen (rituximab, cyclophosphamide ...

OLYMPIA-3 trial at ASCO 2026 shows odronextamab plus CHOP in higher-risk B-cell lymphoma delivers strong MRD-negative CRs ...

Combined-Modality Therapy for Clinical Stage I or II Hodgkin's Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials Untreated ...

Please provide your email address to receive an email when new articles are posted on . The addition of lenalidomide to R-CHOP chemotherapy improved survival outcomes among patients with newly ...

Please provide your email address to receive an email when new articles are posted on . The regimen conferred a 71% complete response rate among older adults with newly diagnosed DLBCL. Median PFS and ...

To participate in this study, patients were required to have a diagnosis of de novo DLBCL; be treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone (R-CHOP) with or without ...

Combined-Modality Therapy for Clinical Stage I or II Hodgkin's Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials Untreated ...